CureVac stock converts into BioNTech shares after merger

Published on 10/04/2026 at 10:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CureVac stock converts at 0.0520 BNTX shares per CVAC share after the completed merger. CureVac's former Tübingen site is scheduled to close in 2027.

CVAC, NL0015436031, Illustration mit AI erstellt.

CureVac stock converts into BioNTech shares after the completed acquisition, with holders receiving 0.0520 new BNTX shares for each CVAC share. The transaction changes the investment case from a standalone biotech listing to a BioNTech integration story.

Merger sets the exchange ratio

CureVac states that BioNTech successfully closed the acquisition and that CureVac is now part of the BioNTech Group. The company identifies BioNTech as Nasdaq-listed BNTX, while the corporate action gives shareholders 0.0520 BNTX shares for every former CVAC share.

Robinhood lists the stock merger on October 2, 2026, and says fractional shares will be retained. That ratio is the key reference for former CVAC holders because it defines the share-based settlement rather than a continuing standalone quotation.

Deal value and operating reset

Multiples reports that BioNTech announced the all-stock transaction on June 12, 2025, at an implied equity value of USD 1.25 billion and an implied value of approximately USD 5.46 per CureVac share. The same account places CureVac revenue at USD 578 million for the transaction comparison.

The historical valuation and the exchange ratio describe two different stages of the deal. The USD 1.25 billion figure measured the announced acquisition, while 0.0520 BNTX shares now defines the shareholder consideration after completion.

Tübingen site faces a 2027 deadline

The operating consequences extend beyond the security. HealthcareMEA reported on October 2, 2026, that the Tübingen site acquired through the CureVac transaction is scheduled to close at the end of 2027, alongside two other German sites.

Tagesschau reported on September 28, 2026, that the three facilities employ about 1,800 people and that the Tübingen location is the former CureVac headquarters. For investors, the merger ratio is the immediate shareholder fact, while the site timetable shows how BioNTech is reshaping the acquired operations.

CVAC becomes a merger record

The completed transaction and the 0.0520 exchange ratio place the former CVAC security in a corporate-action context as of October 2, 2026. CureVac's investor page now directs stakeholders to BioNTech, linking the company's future operating identity to Nasdaq-listed BNTX rather than to an independent CureVac business.